BioAge Labs, Inc. (NASDAQ:BIOA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) have received an average rating of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $43.50.

Several brokerages have commented on BIOA. Oppenheimer began coverage on BioAge Labs in a research note on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price target for the company. Roth Mkm began coverage on BioAge Labs in a research note on Wednesday, May 27th. They set a “buy” rating and a $36.00 price target for the company. BTIG Research began coverage on BioAge Labs in a research note on Wednesday, May 13th. They set a “buy” rating and a $40.00 price target for the company. Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Friday, April 24th.

Institutional Investors Weigh In On BioAge Labs

Large investors have recently modified their holdings of the stock. GSA Capital Partners LLP acquired a new stake in shares of BioAge Labs in the third quarter valued at about $181,000. R Squared Ltd acquired a new stake in shares of BioAge Labs in the third quarter valued at about $154,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of BioAge Labs in the fourth quarter valued at about $1,058,000. Octagon Capital Advisors LP grew its stake in BioAge Labs by 9.4% during the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after purchasing an additional 150,000 shares in the last quarter. Finally, Bank of Nova Scotia purchased a new stake in BioAge Labs during the 1st quarter worth approximately $180,000.

BioAge Labs Trading Up 3.4%

NASDAQ BIOA opened at $21.47 on Tuesday. The company has a market capitalization of $954.41 million, a PE ratio of -8.95 and a beta of 0.94. The business’s 50-day moving average price is $17.54 and its 200 day moving average price is $17.57. BioAge Labs has a twelve month low of $4.07 and a twelve month high of $24.00.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.19. The company had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. Equities analysts predict that BioAge Labs will post -2.68 EPS for the current year.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.